June 3, 2019 / 6:34 AM / 5 months ago

BRIEF-Novartis Announces New Data On Geometry Mono-1 Lung Cancer Study

June 3 (Reuters) - Novartis AG:

* NOVARTIS SHOWS GROWING STRENGTH IN LUNG CANCER INNOVATION WITH NEW CAPMATINIB INVESTIGATIONAL DATA AND NOVEL CANAKINUMAB CLINICAL TRIALS

* PRIMARY ANALYSIS OF INVESTIGATIONAL CAPMATINIB (INC280) IN THE GEOMETRY MONO-1 STUDY DEMONSTRATES PROMISING EFFICACY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET EXON-14 SKIPPING MUTATION

* OVERALL RESPONSE RATE AMONG PATIENTS RECEIVING CAPMATINIB WAS 68% FOR TREATMENT-NAIVE AND 41% FOR PREVIOUSLY TREATED PATIENTS; MEDIAN DURATION OF RESPONSE WAS ALSO CLINICALLY MEANINGFUL IRRESPECTIVE OF PRIOR LINE OF THERAPY Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below